Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GNLX Genelux Corporation

Market Closed 12-12 16:00:00 EST

4.31

-0.09

-2.05%

盘后4.31

+0.000.00%

16:10 EST

High4.53	Low4.17	Vol102.15K
Open4.40	D1 Closing4.40	Amplitude8.18%
Mkt Cap164.00M	Tradable Cap145.41M	Total Shares38.05M
T/O440.18K	T/O Rate0.30%	Tradable Shares33.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GNLX","market":"US","secType":"STK","nameCN":"Genelux Corporation","latestPrice":4.31,"timestamp":1765573200000,"preClose":4.4,"halted":0,"volume":102153,"hourTrading":{"tag":"盘后","latestPrice":4.31,"preClose":4.31,"latestTime":"16:10 EST","volume":10,"amount":43.1,"timestamp":1765573803984},"delay":0,"floatShares":33736900,"shares":38051771,"eps":-0.878138,"marketStatus":"Market Closed","change":-0.09,"latestTime":"12-12 16:00:00 EST","open":4.4,"high":4.525,"low":4.165,"amount":440184.5158,"amplitude":0.081818,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.878138,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1674709200000,"exchange":"NASDAQ","adjPreClose":4.4,"preHourTrading":{"tag":"盘前","latestPrice":4.48,"preClose":4.4,"latestTime":"08:24 EST","volume":100,"amount":448.00000000000006,"timestamp":1765545887245},"postHourTrading":{"tag":"盘后","latestPrice":4.31,"preClose":4.31,"latestTime":"16:10 EST","volume":10,"amount":43.1,"timestamp":1765573803984},"volumeRatio":0.7980017350363658,"impliedVol":0.8307,"impliedVolPercentile":0.2512},"requestUrl":"/m/hq/s/GNLX/tweets","defaultTab":"tweets","newsList":[{"id":"2588062099","title":"Genelux Director John Thomas Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588062099","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588062099?lang=en_us&edition=fundamental","pubTime":"2025-12-03 08:00","pubTimestamp":1764720057,"startTime":"0","endTime":"0","summary":"John Thomas, Director of Genelux Corporation, reported a disposal of common shares of Genelux Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2N2mcx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Genelux Director John Thomas Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2586252292","title":"Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586252292","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586252292?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:00","pubTimestamp":1764162000,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., Nov.  26, 2025  (GLOBE NEWSWIRE) -- Genelux Corporation  (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/26/3195094/0/en/Genelux-Corporation-to-Participate-in-a-Fireside-Chat-at-Piper-Sandler-37th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4581","XBI","HCSG","LU0128526141.USD","BK4137","BK4585","BK4588","XLV","GNLX","LU0029874061.USD","LABU"],"gpt_icon":0},{"id":"2581887576","title":"Genelux Corp. (GNLX) Receives a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2581887576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581887576?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:16","pubTimestamp":1762532191,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer maintained a Buy rating on Genelux Corp. today and set a price target of $16.00. According to TipRanks, Messer is a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/genelux-corp-gnlx-receives-a-buy-from-lake-street-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/genelux-corp-gnlx-receives-a-buy-from-lake-street-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2581856250","title":"Immuno-oncology firm Genelux's Q3 net loss beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2581856250","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581856250?lang=en_us&edition=fundamental","pubTime":"2025-11-06 06:49","pubTimestamp":1762382985,"startTime":"0","endTime":"0","summary":"Immuno-oncology firm Genelux's Q3 net loss beats expectationsOverviewGenelux Q3 net loss of $7.95 mln beats analyst expectationsCompany has $21 mln in cash and investments, funding operations into Q3 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH1KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"gpt_icon":0},{"id":"2581702452","title":"Genelux Corporation posts Q3 net loss of $8.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581702452","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581702452?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:24","pubTimestamp":1762377897,"startTime":"0","endTime":"0","summary":"Genelux Corporation reported a net loss of $8.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $6.5 million, or $0.19 per share, in the same period in 2024. Research and development expenses increased to $4.7 million from $4.1 million, mainly due to higher stock compensation and clinical trial costs. General and administrative expenses rose to $3.5 million from $2.9 million, primarily driven by increased stock compensation and salaries. As of September 30, 2025, Genelux held $21.0 million in cash, cash equivalents, short-term investments, and restricted cash, with a projected cash runway into the third quarter of 2026. Key business developments include continued progress in the Olvi-Vec program for solid tumors, ongoing enrollment in the Phase 3 ovarian cancer trial with topline data expected in the second half of 2026, and advancing lung cancer studies with interim data updates anticipated in the fourth quarter of 2025 and throughout 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL543C0X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4588","IE00BGHQF748.EUR","BK4139","LU2210149790.SGD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","GNLX","LU2095319765.USD","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2581141088","title":"Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581141088","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581141088?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:20","pubTimestamp":1762377600,"startTime":"0","endTime":"0","summary":"-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3182008/0/en/Genelux-Corporation-Reports-Third-Quarter-2025-Financial-Results-and-Provides-General-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2577082428","title":"Genelux price target raised to $20 from $10 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2577082428","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577082428?lang=en_us&edition=fundamental","pubTime":"2025-10-22 01:10","pubTimestamp":1761066640,"startTime":"0","endTime":"0","summary":"Maxim raised the firm’s price target on Genelux (GNLX) to $20 from $10 and keeps a Buy rating on the shares. The firm is lowering its risk adjustme...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genelux-price-target-raised-to-20-from-10-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genelux-price-target-raised-to-20-from-10-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2577678874","title":"Genelux Initiated at Buy by Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2577678874","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577678874?lang=en_us&edition=fundamental","pubTime":"2025-10-21 23:03","pubTimestamp":1761058980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GNLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 21, 2025 11:03 ET (15:03 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2577827452","title":"Genelux initiated with a Buy at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2577827452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577827452?lang=en_us&edition=fundamental","pubTime":"2025-10-21 20:00","pubTimestamp":1761048050,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer initiated coverage of Genelux (GNLX) with a Buy rating and $16 price target The pivotal readout for olvimulogene na...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genelux-initiated-with-a-buy-at-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genelux-initiated-with-a-buy-at-lake-street-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2564231968","title":"Genelux Corporation Concluded Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2564231968","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564231968?lang=en_us&edition=fundamental","pubTime":"2025-09-04 04:06","pubTimestamp":1756929993,"startTime":"0","endTime":"0","summary":"Genelux Corporation held its Annual Meeting of Stockholders on August 27, 2025. During the meeting, stockholders voted on several proposals. The election of Class III Directors was approved, with Thomas Zindrick and James Tyree being elected. Additionally, the selection of the independent registered public accounting firm was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL6tThtM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2564425380","title":"Genelux Corporation to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2564425380","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564425380?lang=en_us&edition=fundamental","pubTime":"2025-09-03 04:01","pubTimestamp":1756843268,"startTime":"0","endTime":"0","summary":"Genelux Corporation , a late clinical-stage immuno-oncology company, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Tuesday, September 9, 2025. Thomas Zindrick, President, CEO and Chairman of the Board, along with Matt Pulisic, Chief Financial Officer, will represent the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via GlobeNewswire  on September 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL1rfD3t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","BK4112","GNLX","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2558693636","title":"Genelux Corp reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2558693636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558693636?lang=en_us&edition=fundamental","pubTime":"2025-08-12 05:01","pubTimestamp":1754946108,"startTime":"0","endTime":"0","summary":"Genelux Corp reports results for the quarter ended June 30 - Earnings SummaryGenelux Corp GNLX.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended June 30, higher than th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nL8N3U31MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX"],"gpt_icon":0},{"id":"2558725575","title":"Genelux Corp  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558725575","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558725575?lang=en_us&edition=fundamental","pubTime":"2025-08-09 04:31","pubTimestamp":1754685067,"startTime":"0","endTime":"0","summary":"Genelux Corp  expected to post a loss of22cents a share - Earnings Preview Genelux Corp GNLX.OQ GNLX.O is expected to  show no change in quarterly revenue when it reports  results  for the period endi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U03GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX"],"gpt_icon":0},{"id":"2557599406","title":"Genelux Q2 EPS $(0.20) Beats $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557599406","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557599406?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:40","pubTimestamp":1754599239,"startTime":"0","endTime":"0","summary":"Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.91 percent. This is a 9.09 percent increase over losses of $(0.22) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46981714/genelux-q2-eps-0-20-beats-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Genelux Q2 EPS $(0.20) Beats $(0.22) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX"],"gpt_icon":0},{"id":"2557280596","title":"Genelux Q2 Operating Expenses USD 7.792 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2557280596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557280596?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:20","pubTimestamp":1754598000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nPLX122754:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2557738599","title":"Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2557738599","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557738599?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:20","pubTimestamp":1754598000,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., Aug.  07, 2025  (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/07/3129750/0/en/Genelux-Corporation-Reports-Second-Quarter-2025-Financial-Results-and-Provides-General-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0},{"id":"2553050194","title":"Genelux Initiated at Buy by LUCID CAPITAL MARKETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2553050194","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553050194?lang=en_us&edition=fundamental","pubTime":"2025-07-22 01:45","pubTimestamp":1753119900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GNLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 21, 2025 13:45 ET (17:45 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4099","BK4555","BK4139","BK4596","BK4551"],"gpt_icon":0},{"id":"2549536043","title":"Genelux Corporation Appoints Eric Groen as General Counsel and Head of Business Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2549536043","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549536043?lang=en_us&edition=fundamental","pubTime":"2025-07-07 19:00","pubTimestamp":1751886026,"startTime":"0","endTime":"0","summary":"Genelux Corporation has announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development, effective July 1, 2025. Groen brings over two decades of experience in the life sciences industry, having previously served as General Counsel at Rani Therapeutics and spending 20 years in the legal department at Amgen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via GlobeNewswire  on July 07, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nNDL89rRhL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4533","IE00BJT1NW94.SGD","LU1571399168.USD","BK4599","LU2468319806.SGD","BK4585","IE00B4R5TH58.HKD","BK4007","LU1023059063.AUD","LU1057294990.SGD","LU2095319765.USD","GNLX","LU0868494617.USD","BK4139","BK4539","BK4566","LU1983299246.USD","LU2089984988.USD","LU1061106388.HKD","LU2210149790.SGD","SG9999001440.SGD","LU0889565916.HKD","LU2242646821.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00BKPKM429.USD","BK4588","AMGN","LU0122379950.USD","LU2210150020.SGD","LU2112291526.USD","LU0320765992.SGD","RANI","IE00BFTCPJ56.SGD","BK4581","LU0289739699.SGD","IE0009355771.USD","BK4534","NDAQ","IE0002141913.USD","BK4112","IE00B64PRP62.GBP","LU2242652126.USD","IE00B2B36J28.USD","LU0058720904.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2549536069","title":"Press Release: Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2549536069","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549536069?lang=en_us&edition=fundamental","pubTime":"2025-07-07 19:00","pubTimestamp":1751886000,"startTime":"0","endTime":"0","summary":"WESTLAKE VILLAGE, Calif., July 07, 2025  -- Genelux Corporation , a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025.\"We are delighted to welcome Eric to the executive team,\" said Thomas Zindrick, President, CEO, and Chairman of the Board. \"Eric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory environments will be invaluable in shaping our next phase of growth.\". Mr. Groen is an accomplished executive who has over two decades of leadership in the life sciences industry, driving results, empowering teams, and shaping positive corporate culture. Recognized as a strategic yet hands-on executive, he is passionate about advanci","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4604","GNLX","BK4099","TM","03160","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2548681703","title":"Genelux Corporation Files Initial Beneficial Ownership Statement for Eric Groen, General Counsel & Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2548681703","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548681703?lang=en_us&edition=fundamental","pubTime":"2025-07-03 04:15","pubTimestamp":1751487332,"startTime":"0","endTime":"0","summary":"Genelux Corporation has filed an initial statement of beneficial ownership. The filing mentions Eric Groen as the beneficial owner, holding the position of General Counsel & Secretary at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nNDL9FwGkm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genelux.com","stockEarnings":[{"period":"1week","weight":-0.0711},{"period":"1month","weight":-0.2732},{"period":"3month","weight":0.0911},{"period":"6month","weight":0.4085},{"period":"1year","weight":0.7103},{"period":"ytd","weight":0.8263}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.214452},{"month":2,"riseRate":0.666667,"avgChangeRate":0.448197},{"month":3,"riseRate":0.333333,"avgChangeRate":0.130752},{"month":4,"riseRate":0,"avgChangeRate":-0.216003},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.034852},{"month":6,"riseRate":0.666667,"avgChangeRate":0.036149},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058289},{"month":8,"riseRate":0.666667,"avgChangeRate":0.080908},{"month":9,"riseRate":1,"avgChangeRate":0.122082},{"month":10,"riseRate":0.666667,"avgChangeRate":0.291649},{"month":11,"riseRate":0,"avgChangeRate":-0.218784},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.056729}],"exchange":"NASDAQ","name":"Genelux Corporation","nameEN":"Genelux Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Genelux Corporation(GNLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Genelux Corporation,GNLX,Genelux Corporation股票,Genelux Corporation股票老虎,Genelux Corporation股票老虎国际,Genelux Corporation行情,Genelux Corporation股票行情,Genelux Corporation股价,Genelux Corporation股市,Genelux Corporation股票价格,Genelux Corporation股票交易,Genelux Corporation股票购买,Genelux Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Genelux Corporation(GNLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction